aztreonam has been researched along with Enterocolitis, Pseudomembranous in 4 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Enterocolitis, Pseudomembranous: An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with vancomycin and aztreonam was associated with a rapid quantitative reduction in faecal colonisation with enterobacteriaceae, whereas there was no quantitative reduction in colonisation with enterobacteriaceae associated with treatment with vancomycin and gentamicin." | 2.67 | Enterobacteriaceae and neonatal necrotising enterocolitis. ( Langdale, V; Levene, M; MacKay, P; Martin, C; Millar, MR, 1992) |
| "We report on one rare case of recurrent pseudomembranous colitis associated with antibiotic treatment with Aztreonam." | 2.38 | [Antibiotic-associated pseudomembranous colitis--a case report with review of the literature]. ( Hegelmaier, C; Hütig, HB; Kalbheim, HJ, 1991) |
| "Aztreonam was the first compound to emerge that fulfilled the objectives of the program." | 1.27 | Aztreonam: the first monobactam. ( Bonner, DP; Sykes, RB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trifilio, SM | 1 |
| Pi, J | 1 |
| Mehta, J | 1 |
| Millar, MR | 1 |
| MacKay, P | 1 |
| Levene, M | 1 |
| Langdale, V | 1 |
| Martin, C | 1 |
| Hegelmaier, C | 1 |
| Hütig, HB | 1 |
| Kalbheim, HJ | 1 |
| Sykes, RB | 1 |
| Bonner, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as [NCT01513109] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2011-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aztreonam and Enterocolitis, Pseudomembranous
| Article | Year |
|---|---|
Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Aztreonam; Chicago; Ciprofloxacin; Clostridioides d | 2013 |
[Antibiotic-associated pseudomembranous colitis--a case report with review of the literature].
Topics: Adenocarcinoma; Aged; Aztreonam; Colostomy; Enterocolitis, Pseudomembranous; Female; Humans; Hystere | 1991 |
1 trial available for aztreonam and Enterocolitis, Pseudomembranous
| Article | Year |
|---|---|
Enterobacteriaceae and neonatal necrotising enterocolitis.
Topics: Aztreonam; Drug Therapy, Combination; England; Enterobacteriaceae Infections; Enterocolitis, Pseudom | 1992 |
1 other study available for aztreonam and Enterocolitis, Pseudomembranous
| Article | Year |
|---|---|
Aztreonam: the first monobactam.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Bacterial Proteins; beta-Lactamases | 1985 |